New immune combo targets hard-to-treat pancreatic cancer
NCT ID NCT07416240
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This early-phase study tests a combination of two immune cell therapies (activated dendritic cells and CAR-T cells) in 10 people with advanced pancreatic cancer. The goal is to see if this approach is safe and can help the immune system better recognize and attack tumors. Participants must have tumors that show a specific marker called Claudin18.2.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hainan Cancer Hospital
RECRUITINGHaikou, Hainan, 570311, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.